Abstracts tagged "interferons"

Abstract Number: 2009 • 2016 ACR/ARHP Annual Meeting
The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures
JT Merrill¹, R Furie², Victoria P. Werth^3,4, M Khamashta⁵, J Drappa⁶, L Wang⁶ and G Illei⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Northwell Health, Great Neck, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Philadelphia V.A. Medical Center, Philidelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, London, United Kingdom, ⁶MedImmune, Gaithersburg, MD
Background/Purpose: The Phase IIb MUSE study (NCT01438489) of intravenous anifrolumab in 305 patients with moderate to severely active SLE (300 or 1,000 mg vs. placebo,…
Abstract Number: 2057 • 2016 ACR/ARHP Annual Meeting
TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling
Sonya Wolf¹, Tamra J. Reed², Chaim O. Jacob³ and J. Michelle Kahlenberg⁴, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Medicine/Div of Rheumatology, USC School of Medicine, Los Angeles, CA, ⁴Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies, immune complex deposition, elevated production of type I interferons (IFNs),…
Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Ruth D.E. Fritsch-Stork², Marjan A. Versnel³, Ronald H.W.M. Derksen⁴, Joel A.G. van Roon^5,6 and Timothy R.D.J. Radstake^5,6, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands
Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
Abstract Number: 2431 • 2016 ACR/ARHP Annual Meeting
Characterization of Innate Immune Cells in Patients with the Interferon-Mediated Autoinflammatory Diseases Sting Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE)
Bernadette Marrero¹, Yin Liu², Katherine R. Calvo³, Angelique Biancotto⁴, Yan Huang¹, Adriana Almeida de Jesus¹, Gina A. Montealegre Sanchez¹ and Raphaela Goldbach-Mansky⁵, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²Scientific Review Branch, NIAMS, NIH, Bethesda, MD, ³Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, ⁴Center for Human Immunology, Autoimmunity and Inflammation, NHLBI/NIH, Bethesda, MD, ⁵Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: We recently described two rare autoinflammatory interferonopathies, STING Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and…
Abstract Number: 2565 • 2016 ACR/ARHP Annual Meeting
Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Karen Fernandez¹, Tracy Doyle², Lisa Harlow³, Ivan O. Rosas⁴ and Dana P. Ascherman⁵, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ³Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, ⁴BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) which contributes to increased morbidity and mortality. Clinico-epidemiological data indicate some overlap…
Abstract Number: 2810 • 2016 ACR/ARHP Annual Meeting
Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing
Grant Hughes¹, Christian Lood², Uche Obih¹ and David Koelle¹, ¹University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The interferon gamma (IFN-G) release assay (IGRA) estimates probability of latent TB infection (LTBI) based on IFN-G released by whole blood after 18h exposure…
Abstract Number: 2878 • 2016 ACR/ARHP Annual Meeting
Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE
Mikhail Olferiev¹, Kyriakos A. Kirou², David Fernandez³, Khalili Leila¹, Dina Greenman¹ and Mary K. Crow⁴, ¹Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, ⁴Department of Medicine, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: All lymphocyte populations contribute to SLE pathogenesis, but little is known of the specific gene transcripts particularly involved in each cell type. Activation of…
Abstract Number: 3006 • 2016 ACR/ARHP Annual Meeting
IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)
Claudia Bracaglia¹, Denise Pires Marafon², Ivan Caiello², Kathy de Graaf³, Florence Guilhot³, Walter Ferlin³, Sergio Davì⁴, Grant Schulert⁵, Angelo Ravelli⁴, Alexei Grom⁶, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland, ⁴Istituto Giannina Gaslini, Genoa, Italy, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Evidence in animals and humans points to a pivotal role of IFNγ in primary HLH. We have recently generated data in an animal model…
Abstract Number: 3220 • 2016 ACR/ARHP Annual Meeting
Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis
Theresa L. Wampler Muskardin¹, Wei Fan², Zhongbo Jin³, Mark A. Jensen⁴, Jessica M. Dorschner³, Yogita Ghodke-Puranik³, Kerry Wright¹, John M. Davis III⁵, Eric L. Matteson¹, Clement Michet Jr.¹, Thomas G. Mason II⁶, Scott T. Persellin⁷, Daniel Schaffer¹, Betty Dicke¹, Danielle Vsetecka³ and Timothy B. Niewold⁸, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology - Department of Medicine, Mayo Clinic Rochester, Rochester, MN, ⁷Department of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁸Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: In rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy, and remission is…
Abstract Number: 761 • 2016 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus
L Santiago¹, B Wang², P Brohawn², L Wang², G Illei² and L Roskos², ¹MedImmune, Mountain View, CA, ²MedImmune, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon–α receptor (IFNAR1) currently in development for the…
Abstract Number: 774 • 2016 ACR/ARHP Annual Meeting
BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers
David Martin, Lauren Stevenson, Pratapa Prasad, Karen Smirnakis, Amy Kao, Dania Rabah, Wenting Wang and Nathalie Franchimont, Biogen, Cambridge, MA
Background/Purpose: Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). In SLE, immune complexes stimulate plasmacytoid dendritic cells (pDCs) to…
Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting
Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts
Georg Pongratz¹, Rainer Straub² and Torsten Lowin³, ¹Rheumatology - Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany, ²Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…
Abstract Number: 1251 • 2015 ACR/ARHP Annual Meeting
Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases
Tamarah D. de Jong¹, Saskia Vosslamber¹, Elise Mantel¹, Sander de Ridder¹, John G. Wesseling¹, Tineke C.T.M. van der Pouw Kraan², Joep Killestein³, Ingrid E. Lundberg⁴, Jiri Vencovsky^5,6, Irene E.M. Bultink⁷, Alexandre E. Voskuyl⁸, Michiel Pegtel¹, Conny J. van der Laken⁹, Johannes W. Bijlsma⁸ and Cornelis L. Verweij¹, ¹Pathology, VU University medical center, Amsterdam, Netherlands, ²Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands, ³Neurology, VU University medical center, Amsterdam, Netherlands, ⁴Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁹Rheumatology, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Presence of a type I interferon (IFN) signature is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM)…
Abstract Number: 1525 • 2015 ACR/ARHP Annual Meeting
Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes
Shogo Banno¹, Shiho Iwagaitsu², Taio Naniwa³, Hironobu Nobata⁴, Hirokazu Imai⁴, Shinya Tamechika², Shinji Maeda² and Akio Niimi², ¹Rheumatology and Nephrology, Aichi Medical University School of Medicine, Aichi-prefecture, Japan, ²Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya City, Japan, ³Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya city, Japan, ⁴Rheumatology and Nephrology, Aichi Medical University School of Medicine, Nagakute City, Japan
Background/Purpose: We aimed to evaluate the performance of QFT-GIT and T-SPOT.TB assays to predict the risk of latent tuberculosis infection (LTBI) in Japanese rheumatoid arthritis…
Abstract Number: 1805 • 2015 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Jeffrey Riggs¹, Brian Naiman², Jing Zhang¹, Yan Xu¹, Inna Vainshtein³, Carl Hay¹, Kevin Schifferli¹, Pina Cardarelli⁴, Meina Liang⁵, Lorin Roskos⁶, Jane Connor⁷, Roland Kolbeck⁸, Anthony Coyle⁹ and Michael Fung¹, ¹MedImmune LLC, Gaithersburg, MD, ²Research, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Hayward, CA, ⁴Medarex, Sunnyvale, CA, ⁵PKPD&Bioanalysis, MedImmune LLC, Hayward, CA, ⁶MedImmune LLC, Mountain View, CA, ⁷Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ⁸Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, ⁹Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA
Background/Purpose: Increased type I interferon (IFN) activities are associated with the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab, a fully human, IgG1 κ monoclonal antibody…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].